Comparison of Serplulimab Versus Nivolumab in Neoadjuvant Therapy for Resectable Stage II-IIIA Squamous NSCLC

Exclusion Criteria

• •1. Other pathological histological types of non-small cell lung cancer subjects, including adenocarcinoma subjects, squamous-adenocarcinoma mixed cancer subjects, and NSCLC containing components of small cell lung cancer and neuroendocrine carcinoma.
• •2. EGFR sensitivity mutation or ALK, ROS1 gene rearrangement;
• •3. Known severe allergy to any components of carboplatin/albumin paclitaxel and other drugs;
• •4. Central nervous system (CNS) or leptomeningeal metastases confirmed by imaging or pathology